Biocept Akcija

Biocept ROE

Delisted

Vrijednost ROE (Return on Equity) od Biocept (BIOC) na dan 11. авг 2026. je -362,16 %. Prethodne godine, ROE (Return on Equity) je bio -7,53 % — promjena od 4.706,51% (niži).

ROE

-362,16 %

YoY

4.706,51%

Zadnja ažuriranja:

U godini 2026 rentabilnost sopstvenog kapitala (ROE) kompanije Biocept iznosila je -362,16 %, što je porast od 4.706,51% u poređenju sa -7,53 % ROE prethodne godine.

Access this data via the Eulerpool API

Biocept Анализа акција

Šta radi Biocept? Biocept Inc is a biotechnology company based in San Diego, California. It was founded in 1997 by Michael W. Nall, an experienced entrepreneur in the field of medical diagnostics and cancer research. Biocept specializes in the development of diagnostic tests and platforms aimed at the rapid and precise identification of cancer cells in the human body. The business model of Biocept focuses on the development of cancer diagnostic tests and selling them to medical labs, physician offices, and hospitals. The company offers a range of different diagnostic products that specialize in various types and stages of cancer. One of Biocept's most important products is a liquid biopsy test that allows medical professionals to quickly and effectively detect cancer cells in patients' blood. This test is particularly significant as it enables doctors to detect cancer at an early stage, thus improving treatment options and increasing the cure rate. Additionally, Biocept offers a variety of tests targeting specific types of cancer such as breast, lung, and prostate cancer. These tests are based on the analysis of tumor DNA extracted from tumor cells in biopsies or liquid biopsies. By accurately analyzing this DNA, medical professionals can determine the specific type and stage of the cancer, thus recommending the best treatment option. In order to expand its range of diagnostic products, Biocept has also entered into partnerships with other companies and research institutions in recent years. For example, in 2017, the company entered into a collaboration with Massachusetts General Hospital to develop a new panel of liquid biopsy tests specializing in the identification of cancer cells in various tissues and organs. Biocept has experienced strong growth in recent years, and its products are now sold in a variety of countries worldwide. The company works closely with medical professionals and research institutions to continuously improve its diagnostic products and develop new tests tailored to the needs of patients with cancer. The output isn't a question, so there is no answer needed. Biocept je jedna od najpopularnijih kompanija na Eulerpool.

ROE у детаљу

Razjašnjenje povrata na sopstveni kapital (ROE) kompanije Biocept

Povraćaj na sopstveni kapital (ROE) kompanije Biocept je osnovni pokazatelj koji ocenjuje profitabilnost kompanije u odnosu na sopstveni kapital. ROE, izračunat deljenjem neto dobiti sa sopstvenim kapitalom akcionara, ilustruje efikasnost kompanije u ostvarivanju profita iz investicija akcionara. Viši ROE označava povećanu efikasnost i profitabilnost.

Poređenje iz godine u godinu

Analiza ROE kompanije Biocept iz godine u godinu pomaže u praćenju trendova profitabilnosti i finansijskih performansi. Rastući ROE ukazuje na povećanu profitabilnost i stvaranje vrednosti za akcionare, dok opadajući ROE može ukazivati na probleme u stvaranju dobiti ili upravljanju sopstvenim kapitalom.

Uticaj na investicije

ROE kompanije Biocept je ključan za investitore koji ocenjuju profitabilnost, efikasnost i privlačnost kompanije kao investicije. Robusni ROE ukazuje na sposobnost kompanije da pretvori investicije sopstvenog kapitala u profit, čime povećava svoju privlačnost potencijalnim i sadašnjim investitorima.

Interpretacija fluktuacija ROE

Promene u ROE kompanije Biocept mogu proizaći iz fluktuacija neto dobiti, sopstvenog kapitala ili oboje. Ove fluktuacije se analiziraju sa ciljem procene efikasnosti menadžmenta, finansijskih strategija, kao i povezanih rizika i mogućnosti, te pomažu investitorima u donošenju obrazloženih odluka.

Često postavljena pitanja o akciji Biocept

ROE (Return on Equity) kompanije Biocept iznosi -362,16 % u 2026. godini.

ROE (Return on Equity) od Biocept se promijenio sa -7,53 % na -362,16 %, što predstavlja promjenu od 4.706,51%. Vrijednost je niži nego prethodne godine.

Na Eulerpool-u možete pronaći potpuni historijski razvoj ROE (Return on Equity) Biocept od 2006. — sa godišnjim vrijednostima, grafikonima i detaljnom analizom.

Dobar varira u zavisnosti od industrije i faze razvoja preduzeća. Na Eulopoolu, možete porediti ROE (Return on Equity)'s Biocept sa sličnim preduzećima u sektoru i prosekom industrije da biste proverili da li je atraktivan.

Da biste proverili ROE (Return on Equity)'s, bitno je da ga uporedite sa konkurentima u istoj industriji i sektoru. Na Eulopoolu, možete pronaći direktna upoređivanja industrije za ROE (Return on Equity).

Access this data via the Eulerpool API

Профитабилност — Biocept

Sve ključne metrike — Biocept

Раст